TCR2 Therapeutics Inc. (TCRR)
| Market Cap | 474.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -73.13M |
| Shares Out | 37.06M |
| EPS (ttm) | -2.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $12.85 |
| Previous Close | $12.85 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 12.94 |
| Day's Range | 12.42 - 12.98 |
| Day's Volume | 91,069 |
| 52-Week Range | 12.15 - 35.86 |
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with solid ...
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from canc...
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from canc...
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...
- Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from c...
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from ca...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for ...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for ...
- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21
- TC-210 induced tumor regression in all of the first eight patients
CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering f...
- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20
CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from...
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from...
- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75%
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies fo...
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies fo...
The company announced positive interim results for one of its experimental treatments.
- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering...
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients ...
CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients s...
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients s...
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients...
About TCRR
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignanci... [Read more...]
| Industry Biotechnology | IPO Date Feb 14, 2019 |
| CEO Garry Menzel | Employees 131 |
| Stock Exchange NASDAQ | Ticker Symbol TCRR |
Analyst Forecasts
According to 9 analysts, the average rating for TCRR stock is "Strong Buy." The 12-month stock price forecast is 42.60, which is an increase of 231.52% from the latest price.